Quantcast

Latest Sofinnova Stories

2014-07-23 08:30:21

SVP IX fund to invest primarily in late-stage biopharmaceutical companies MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park based investment firm, today announced the closing of Sofinnova Venture Partners IX, L.P. at the hard cap of $500 million and in excess of the initial fund target of $425 million. http://photos.prnewswire.com/prnvar/20130724/SF52046LOGO-b Sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology...

2014-07-16 12:27:18

MADRID, July 16, 2014 /PRNewswire/ -- Biospain 2014 is currently seeking and selecting projects for presentation as part of its Investment Forum, one of the most high profile in the sector, for which 25 investment funds - 70% of which are international- have already confirmed their attendance, a figure the organisers expect to double. (Logo: http://photos.prnewswire.com/prnh/20140716/697032 ) This year the Forum will be bolstered by the presence of a wider...

2014-06-18 12:39:39

SUNNYVALE, Calif., June 18, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced the appointment of Jay Shepard and William D. Waddill to the company's Board of Directors. Mr. Shepard currently serves as an Executive Partner at Sofinnova Ventures and has more than 32 years of commercial and company building experience in the specialty pharmaceutical and biotechnology industry. Mr....

2014-06-16 08:29:08

Company will draw on leaders' expertise in rare diseases, R&D and commercialization as it moves to complete development of its lead program in inherited blindness PHILADELPHIA, June 16, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today the appointments of Lars Ekman, former president of research and development at Elan, and Vin Milano, former president and CEO of...

2014-05-27 16:25:11

Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, today announced the successful completion of a $72.8 million Series B financing led by Sofinnova Ventures. Joining Sofinnova as new investors in the company are Brookside...

2014-05-19 08:28:28

REDWOOD CITY, Calif., May 19, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), a leading biologics platform company focused on biosimilars, announced today the closing of a Series C Preferred investment round raising $55 million. New investors KKR & Co. L.P. ("KKR"), Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital in the transaction. "We are very pleased to have...

2014-05-16 04:23:16

SAN FRANCISCO, May 16, 2014 /PRNewswire/ -- OpenERP has raised $10 million dollars in funding to support its R&D efforts and commercial growth. As part of the growth strategy OpenERP is rebranding to Odoo, to better reflect its expanded areas of focus in CMS & Ecommerce and POS applications beyond the core ERP function. Odoo has improved its pricing and included a free version for up to two users for very small businesses to enjoy a completely integrated suite of...

2014-05-15 12:36:56

LONDON, May 15, 2014 /PRNewswire/ -- BioTrinity's move to London a record success: attendance breaks the 1,000 mark OBN - the membership organisation supporting the UK's emerging life sciences companies - announces today that BioTrinity, its annual conference, has achieved record attendance, with 1,000 delegates present, building on its position as the leading biopartnering and investment conference in Europe. Jon Rees, CEO of OBN, said: "The success of our first...

2014-04-03 04:20:52

CAMBRIDGE, England, April 3, 2014 /PRNewswire/ -- GBP19.5M raised to drive development of best-in-class fully human VH antibody fragment therapeutics Crescendo Biologics Limited (Crescendo) today announces it has raised a further GBP2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals GBP19.5m. It was led by Imperial Innovations and included new...

2014-03-28 04:21:52

CAMBRIDGE, England, March 28, 2014 /PRNewswire/ -- Crescendo Biologics Limited (Crescendo) today announces it has been awarded the prize for Business Innovation at the Cambridge News Business Excellence Awards 2014. During 2013, Crescendo announced the Crescendo Mouse, a breakthrough in antibody fragment technology which allows the efficient generation of high-quality fully human single domain antibody VH fragments from a transgenic mouse. The Company also raised...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related